Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD).
For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).
|10/07/19||8-K||Current report filing||5|
|10/03/19||8-K||Current report filing||5|
|09/16/19||8-K||Current report filing||6|
|09/16/19||8-K||Current report filing||26|
|09/12/19||424B3||Prospectus filed pursuant to Rule 424(b)(3)||34|
|09/11/19||EFFECT||Notice of Effectiveness||1|
|09/09/19||CORRESP||A correspondence can be sent as a document with another submission type or can be sent as a separate submission.||2|
|09/06/19||CORRESP||A correspondence can be sent as a document with another submission type or can be sent as a separate submission.||2|
|09/06/19||S-1/A||General form of registration statement for all companies including face-amount certificate companies||47|